Axogen (AXGN): Insider sold 32,191 shares at $18 on Oct 2-3
William P. Burke, a director of Axogen, Inc. (AXGN), reported multiple sales of common stock on 10/02/2025 and 10/03/2025.
Rhea-AI Filing Summary
William P. Burke, a director of Axogen, Inc. (AXGN), reported multiple sales of common stock on 10/02/2025 and 10/03/2025. The filings show four sale entries totaling 32,191 shares sold from both Mr. Burke and the Elizabeth J. Burke 2024 Irrevocable Trust. The reported sale prices are shown as weighted averages with executed price ranges between $18.00 and $18.60 per share.
The Form 4 states the transactions were made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. After the reported transactions the schedule shows 2,293 shares held directly and 0 shares held indirectly by the trust in the most recent line, reflecting the post-transaction beneficial ownership reported on the form.
Positive
- Trades executed under a Rule 10b5-1(c) plan adopted March 14, 2025, indicating preplanned, documented transactions
- Weighted-average pricing disclosed with price ranges provided ($18.00–$18.60), improving transparency about execution
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,600 | $18.2062 | $138K |
| Sale | Common Stock | 14,571 | $18.2062 | $265K |
| Sale | Common Stock | 2,400 | $18.01 | $43K |
| Sale | Common Stock | 7,620 | $18.0053 | $137K |
Footnotes (4)
- F1. The sale from the Elizabeth J. Burke 2024 Irrevocable Trust, of which William P. Burke is a stakeholder and a Trustee, reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.04 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2. The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.02 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3. The sale is from the Elizabeth J. Burke 2024 Irrevocable Trust, of which William P. Burke is a stakeholder and a Trustee.
- F4. The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.60 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Axogen director William P. Burke report on Form 4 (AXGN)?
Were the sales by William P. Burke part of a trading plan?
Which trust was involved in the reported sales?
What price details are disclosed on the Form 4 for these transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.